Serum alpha-fetoprotein kinetics as a mechanistic biomarker for rAAV-TK/GCV efficacy in hepatocellular carcinoma
American Journal of Translational Research · 2026 · 18 (5) · 4082-4096
DOI: 10.62347/pnpk1326 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Jianmao Yang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, General Technology Aerospace Medicine, Baogang Hospital of Inner Mongolia Baotou 014010, Inner Mongolia, China. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, General Technology Aerospace Medicine, Baogang Hospital of Inner Mongolia Baotou 014010, Inner Mongolia, China.
- Department of Burn Surgery, General Technology Aerospace Medicine, Baogang Hospital of Inner Mongolia Baotou 014010, Inner Mongolia, China.
Zitieren
APA
Yang, J., & Cao, S. (2026). Serum alpha-fetoprotein kinetics as a mechanistic biomarker for rAAV-TK/GCV efficacy in hepatocellular carcinoma. American Journal of Translational Research, 18(5), 4082-4096. https://doi.org/10.62347/pnpk1326
Vancouver
Yang J, Cao S. Serum alpha-fetoprotein kinetics as a mechanistic biomarker for rAAV-TK/GCV efficacy in hepatocellular carcinoma. American Journal of Translational Research. 2026;18(5):4082-4096. doi:10.62347/pnpk1326
BibTeX
@article{Yang2026,
author = {Yang, Jianmao and Cao, Shengjun},
title = {Serum alpha-fetoprotein kinetics as a mechanistic biomarker for rAAV-TK/GCV efficacy in hepatocellular carcinoma},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {5},
pages = {4082--4096},
doi = {10.62347/pnpk1326}
}
EUVIMED